Drug–Drug Interaction Assessment of WXFL10203614 with Rifampicin, Itraconazole and Metformin: A Three-Cohort Phase I Study
This Phase I study demonstrates that the JAK1 inhibitor WXFL10203614 is sensitive to CYP3A4 modulation by rifampicin and itraconazole, which significantly alter its systemic exposure, while WXFL10203614 at steady state reduces metformin renal clearance via MATE transporter inhibition without causing clinically meaningful changes in metformin plasma levels or safety.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When the body fights an overactive immune system, a specific set of internal switches called JAK1 often gets stuck in the "on" position, driving inflammation that causes pain and damage in conditions like rheumatoid arthritis and skin diseases. To turn these switches off, scientists design small molecules that act like precise keys, fitting into the JAK1 lock to stop the signal. However, the human body is a complex chemical factory where drugs rarely travel alone. They must navigate a landscape filled with other medicines, food, and the body's own cleaning crews. These cleaning crews are enzymes that break down foreign substances and transporters that shuttle them out of cells. If a new drug meets a strong inducer, a substance that speeds up the cleaning crews, the drug might vanish before it can work. If it meets a strong inhibitor, a substance that blocks the crews, the drug might pile up to dangerous levels. Understanding these interactions is not just a matter of theory; it is a safety requirement for anyone who might take a new medicine alongside their existing prescriptions.
Researchers recently put a new JAK1 inhibitor, known as WXFL10203614, through a rigorous test to see how it behaves when mixed with other common drugs. The study involved fifty-four healthy adults who took the new medicine under different conditions. In the first part of the investigation, the team wanted to see what happened when the body's cleaning crews were either supercharged or blocked. They gave one group of participants a strong inducer called rifampicin, which is known to wake up the liver's main drug-breaking enzyme, and another group a strong inhibitor called itraconazole, which puts that same enzyme to sleep. The results showed that the new drug is highly sensitive to these changes in the liver's activity. When the participants took rifampicin, the amount of the new drug circulating in their blood dropped by about forty percent, and it left their system much faster. This suggests that if a patient takes this new medicine with a strong inducer, the drug might not stay in the body long enough to be effective. Conversely, when the participants took itraconazole, the drug levels rose by about twenty-six percent. While this increase was noticeable, it did not reach a level that the researchers considered dangerous or requiring a change in how the drug is given.
The second part of the study looked at the new drug from the opposite angle: could it interfere with other medicines the patient might already be taking? The researchers focused on metformin, a very common drug used to treat high blood sugar. Metformin is unique because it does not rely on the liver to break it down; instead, it is cleared from the body by specific transporters in the kidneys that act like a conveyor belt, moving the drug into the urine. The team gave participants the new JAK1 inhibitor until it reached a steady level in their system, and then they added a single dose of metformin. They found that the new drug did not significantly change the total amount of metformin floating in the blood. However, when they looked at the urine, a different story emerged. The amount of metformin excreted in the urine dropped by about thirty percent, and the speed at which the kidneys cleared the drug slowed down by roughly thirty-six percent. This indicates that the new drug was temporarily blocking the kidney's conveyor belt, causing the metformin to stay in the body a little longer than usual.
Throughout the entire study, the new medicine was well tolerated. Most side effects were mild, such as temporary changes in heart rate or blood pressure, and no serious safety issues arose. The one exception was a single participant who stopped the study due to a rise in liver enzymes while taking the new drug alone, but this was not linked to the drug interactions. The findings paint a clear picture for future use. The new drug should not be taken at the same time as strong inducers like rifampicin, as this would likely render the treatment ineffective. While it can be taken with strong inhibitors like itraconazole without major concern, doctors should be cautious when prescribing it alongside metformin or similar drugs that rely on kidney transporters, as the combination could lead to a buildup of the other drug. By mapping out exactly how this new molecule interacts with the body's cleaning systems, the study provides the necessary safety guidelines to ensure that patients can use this promising treatment without unexpected surprises.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.